Twelve month run-up to the Afrezza approval in conjunction with a "big pharma" marketing partnership for Afrezza, another development partnership for one of the cancer drugs, and several Technosphere license agreements with other drug companies moves the share price to the $12.00 range or higher within a year.
Check the one year chart on MDVN.
The annual market for drugs to treat diabetes just in the United States will be over $55 billion dollar by the year 2020. The world wide market will be ten times that amount.
Mannkind is currently substantially undervalued.
TheStreet.com is correct that Mannkind is due for a technical breakout. I suggest you buy a few shares before you miss the gap higher and the subsequent approval run.